As of 2026-07-19, the Relative Valuation of Nektar Therapeutics (NKTR) is (85.99) USD. This relative valuation is based on P/E multiples. With the latest stock price at 68.26 USD, the upside of Nektar Therapeutics based on Relative Valuation is -226.0%.
The range of the Relative Valuation is (89.88) - (84.70) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.4x - 27.4x | 20.8x |
| Forward P/E multiples | 15.3x - 18.3x | 16.4x |
| Fair Price | (89.88) - (84.70) | (85.99) |
| Upside | -231.7% - -224.1% | -226.0% |
| Date | P/E |
| 2026-07-15 | -14.77 |
| 2026-07-14 | -14.53 |
| 2026-07-13 | -14.78 |
| 2026-07-10 | -15.22 |
| 2026-07-09 | -15.77 |
| 2026-07-08 | -15.55 |
| 2026-07-07 | -16.20 |
| 2026-07-06 | -15.82 |
| 2026-07-02 | -15.37 |
| 2026-07-01 | -13.93 |
| 2026-06-30 | -15.10 |
| 2026-06-29 | -14.14 |
| 2026-06-26 | -13.77 |
| 2026-06-25 | -13.42 |
| 2026-06-24 | -14.02 |
| 2026-06-23 | -14.43 |
| 2026-06-22 | -14.21 |
| 2026-06-18 | -13.19 |
| 2026-06-17 | -13.18 |
| 2026-06-16 | -13.04 |
| 2026-06-15 | -13.23 |
| 2026-06-12 | -12.84 |
| 2026-06-11 | -12.81 |
| 2026-06-10 | -12.28 |
| 2026-06-09 | -12.16 |
| 2026-06-08 | -12.25 |
| 2026-06-05 | -12.40 |
| 2026-06-04 | -12.83 |
| 2026-06-03 | -12.81 |
| 2026-06-02 | -12.67 |
| 2026-06-01 | -13.81 |
| 2026-05-29 | -14.03 |
| 2026-05-28 | -14.06 |
| 2026-05-27 | -14.15 |
| 2026-05-26 | -14.18 |
| 2026-05-22 | -14.41 |
| 2026-05-21 | -14.83 |
| 2026-05-20 | -15.03 |
| 2026-05-19 | -14.62 |
| 2026-05-18 | -14.80 |
| 2026-05-15 | -15.28 |
| 2026-05-14 | -16.08 |
| 2026-05-13 | -16.43 |
| 2026-05-12 | -16.96 |
| 2026-05-11 | -17.03 |
| 2026-05-08 | -17.71 |
| 2026-05-07 | -18.03 |
| 2026-05-06 | -18.40 |
| 2026-05-05 | -18.20 |
| 2026-05-04 | -18.79 |